Menu
Recruiting NCT06848387

Unbound Cloxacillin Concentrations During Continuous Infusion

Phase IV Interventional Staphylococcal Infections

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Unbound cloxacillin concentration.
Who it may be relevant to
Registry conditions: Staphylococcal Infections. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Sweden
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Concentration of Unbound Cloxacillin in Adults Treated With Continuous Infusion Via Elastomeric Pump

Overview

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.

Interventions

  • Diagnostic test Unbound cloxacillin concentration
    Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.

Primary outcome measures

  • Free (unbound) cloxacillin concentration [Time frame: From enrollment to end of follow up at 48 hours]

Eligibility criteria

Inclusion criteria

  • Age 18 years or older
  • Treating physician has decided to start continuous infusion of cloxacillin

Exclusion criteria

  • Unwilling or unable to provide written informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

Sweden · 1 center
  • Västmanlands sjukhus Västerås — Västerås

Identifiers

NCT: NCT06848387 · 992496/KLONC

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗